Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avacta GroupAVCTF 23 Cash-to-Debt is 1.13 as of Dec. 2025, which is 93% below its 10-year median of 15.38. GuruFocus rates AVCTF with a GF Score™ of 23/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,393 Biotechnology companies, Avacta Group ranks worse than 76.02% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Avacta Group's cash to debt ratio for the quarter that ended in Dec. 2025 was 1.13.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Avacta Groupcould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Avacta Group's Cash-to-Debt or its related term are showing as below:
AVCTF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.53 Med: 15.38 Max: No Debt
Current: 1.13
During the past 13 years, Avacta Group's highest Cash to Debt Ratio was No Debt. The lowest was 0.53. And the median was 15.38.
AVCTF's Cash-to-Debt is ranked worse than 76.02% of 1393
companies
in the Biotechnology industry
Industry Median: 6.72
vs AVCTF: 1.13
Avacta Group (OTCPK:AVCTF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Avacta Group Cash-to-Debt Related Terms
Avacta Group Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Avacta Group's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
AVCTF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Avacta Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Avacta Group's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (AVCTF) has a Cash-to-Debt of 1.13 as of Dec. 2025. This is 93% below median its historical median of 15.38. Over the past decade, Avacta Group's Cash-to-Debt has ranged from 0.53 to 10,000.00. According to the industry distribution chart, Avacta Group ranks #1059 out of 1393 companies in the Biotechnology industry, placing it in the top 76%.
Is Avacta Group's Cash-to-Debt too high?
Avacta Group's current Cash-to-Debt of 1.13 is 93% below median its 10-year median of 15.38. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.72. Avacta Group's value of 1.13 is 83.2% below this industry median. Based on the distribution chart, Avacta Group ranks #1059 out of 1393 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #1059 out of 1393 companies for Cash-to-Debt. This places Avacta Group in the lower half of its industry. The industry median Cash-to-Debt is 6.72. Avacta Group's value of 1.13 is 83.2% below this benchmark. Historically, Avacta Group's own Cash-to-Debt has ranged from 0.53 to 10,000.00 over the past decade. While the company's 10-year median is 15.38 vs. the industry median of 6.72, Avacta Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current Cash-to-Debt of 1.13 is 83.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current Cash-to-Debt is 1.13, which is 93% below median its own 10-year median of 15.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $0.94 — trading 43.9% above its estimated fair value. The current Cash-to-Debt is 1.13, which is 93% below median its 10-year median of 15.38 and 83.2% below the Biotechnology industry median of 6.72. Avacta Group's overall GF Score™ is 23/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Avacta Group (AVCTF), the current Cash-to-Debt is 1.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $0.94 is trading 43.9% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
Cash-to-Debt: 1.13 (93% below median its 10-year median of 15.38)
GF Value™: $0.65 vs. price of $0.94 (43.9% above fair value)
Industry Position: 83.2% below the Biotechnology median (#1059 of 1393)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
23GF Score
Get the complete analysis for AVCTF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
